RAS mutation status in colorectal cancer
- Date: 20 Apr 2015
- Topic: Colon Cancer / Rectal Cancer / Translational Research
Speaker: Marc Peeters
Marc Peeters interpret results of expanded RAS analysis in the CRYSTAL and OPUS studies in metastatic colorectal cancer and post-hoc analysis of KRAS status in the adjuvant PETACC8 trial.
Discussion Points
- OPUS - Extended RAS analysis
- Do biomarkers have a prognostic role in the adjuvant setting?
Abstracts Discussed
- O-0020 - Outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer randomized to FOLFIRI with or without cetuximab as first-line treatment
- O-0021 - Outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer randomized to FOLFOX4 with or without cetuximab as first-line treatment
- O-0024 - Prognostic value of KRAS mutations in stage III colon cancer: post-hoc analyses of the PETACC8 phase III trial